|
Video: What is a Stock Split?
|
|
ImmunoCellular Therapeutics is a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of cancers. Co.'s clinical product candidates include: ICT-107, which is a dendritic cell (DC) immunotherapy for the treatment of newly diagnosed glioblastoma multiforme, a lethal type of brain cancer; ICT-140, which is a DC immunotherapy that targets seven tumor-associated antigens expressed on ovarian cancer cells; and ICT-121, which specifically targets CD133, a cancer stem cell marker that is in a variety of solid tumors, including ovarian, pancreatic, and breast cancers. According to our IMUC split history records, IMUC has had 1 split. | |
|
IMUC (IMUC) has 1 split in our IMUC split history database. The split for IMUC took place on November 21, 2016. This was a 1 for 40 reverse split, meaning for each 40 shares of IMUC owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 25 share position following the split.
When a company such as IMUC conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the IMUC split history from start to finish, an original position size of 1000 shares would have turned into 25 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into IMUC shares, starting with a $10,000 purchase of IMUC, presented on a split-history-adjusted basis factoring in the complete IMUC split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
01/08/2021 |
|
End date: |
10/03/2024 |
|
Start price/share: |
$0.47 |
|
End price/share: |
$0.12 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-75.11% |
|
Average Annual Total Return: |
-31.09% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$2,489.47 |
|
Years: |
3.73 |
|
|
|
Date |
Ratio |
11/21/2016 | 1 for 40 |
|
|